Eli Lilly and Company (NYSE:LLY) Shares Up 1.8% – Here’s Why

by · The Markets Daily

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 1.8% on Friday . The stock traded as high as $1,028.90 and last traded at $1,027.6780. 3,241,517 shares changed hands during trading, a decline of 20% from the average session volume of 4,027,176 shares. The stock had previously closed at $1,009.38.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Tuesday. Sanford C. Bernstein boosted their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research report on Monday, November 24th. National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a report on Monday, December 1st. Finally, HSBC reaffirmed a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,109.24.

Read Our Latest Analysis on LLY

Eli Lilly and Company Trading Up 1.8%

The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a market capitalization of $971.55 billion, a price-to-earnings ratio of 50.28, a price-to-earnings-growth ratio of 1.11 and a beta of 0.37. The firm has a fifty day moving average price of $935.73 and a 200-day moving average price of $816.80.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of LLY. Laurel Wealth Advisors LLC grew its position in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $8,827,714,000. Capital Research Global Investors boosted its stake in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after acquiring an additional 1,183,038 shares during the last quarter. Finally, Amundi lifted its holdings in Eli Lilly and Company by 27.1% during the third quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after acquiring an additional 964,675 shares during the period. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More